Compare ADMA Biologics Inc (ADMA) vs Global X FTSE Southeast Asia ETF (ASEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Global X FTSE Southeast Asia ETF — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Global X FTSE Southeast Asia ETF trades at $21.47. The key difference: Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | ASEA | |
|---|---|---|
Market Cap | $2.18B | — |
Sector | Health | Sector/Thematic |
52-Week High | $20.38 | $21.53 |
52-Week Low | $7.60 | $16.86 |
Enterprise Value | $2.25B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
ASEA trades at $21.53, up 1.41% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows uniform support and resistance at $21. Key financial ratios are unavailable, but a dividend of $0.41 is scheduled for July 2026. Recent business developments and earnings data are not provided, limiting fundamental assessment.
The outlook is cautiously optimistic due to strong technical momentum, though the absence of current financial metrics and news increases uncertainty. Investment opportunity hinges on upcoming financial disclosures, while risks include data gaps and market volatility. Investors should await earnings reports for clearer valuation insights.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →
